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Cachexia is the most common paraneoplastic syndrome in cancer
with about one-half of untreated cancer patients having lost some
weight at the time of presentation (De Wys et al, 1980). There is a
reduction in both body fat and lean body mass, but while there
is marked depletion of skeletal muscle, the non-muscle protein
compartment is relatively preserved, thus differentiating cancer
cachexia from simple starvation (Fearon, 1992).
A number of cytokines, including tumour necrosis factor-a
(TNF-a) (Beutler and Cerami, 1986), interleukin-1 (IL-1)
(Moldawer et al, 1988), interleukin-6 (IL-6) (Strassman et al,
1992), interferon-g (IFN-g) (Matthys et al, 1991) and leukaemia
inhibitory factor (LIF) (Mori et al, 1989) have been suggested to
play a role in the cachectic process. However, although cytokine
production has been associated with the development of the
cachectic syndrome induced by some human tumour cell lines, in
others cachexia can occur in the absence of cytokine production,
suggesting that other factors are also involved (Kajimura et al,
1996). Studies from our own laboratory have provided evidence
for the production of a proteolysis-inducing factor (PIF) by both
murine and human tumours (Todorov et al, 1996a). This factor
produces loss of skeletal muscle by decreasing protein synthesis
and increasing protein degradation (Lorite et al, 1997). Unlike the
cytokines, PIF is capable of inducing protein degradation in
isolated skeletal muscle (Todorov et al, 1996b) and produces a
state of cachexia in non-tumour-bearing mice without a reduction
in food and water intake.
Even in cytokine-secreting tumours other factors may be
involved in the development of cachexia, particularly in the
erosion of skeletal muscle mass. In the present study, the produc-
tion of PIF has been determined in a human melanoma cell line,
G361. This tumour has been reported to induce severe cachexia in
tumour-bearing nude mice and this has been correlated with the
expression of LIF (Mori et al, 1991). In addition, biosynthetic
labelling studies have been performed to determine if human PIF
contains the same number and size of oligosaccharide chains as
previously reported in the mouse (Todorov et al, 1997) as well as
the same linking to the polypeptide core.
MATERIALS AND METHODS
Materials
[D-6-3H]Glucosamine hydrochlorinol (sp. act. 18.5 Ci mmol–1)
and sodium [35S] sulphate (sp. act. 10–100 mCi mmol–1) were
purchased from Amersham International (Bucks, UK). Tissue
culture medium and fetal bovine serum (FBS) were from Life
Technologies Inc (Paisley, UK). Peptide N-glycosidase F (PNGase
F) and endo-a-N-acetylgalactosaminidase (O-glycosidase) were
obtained from Oxford Glycosystems Ltd (Oxford, UK). Pure
strain NMRI mice were obtained from our own inbred colony and
were fed a rat and mouse breeding diet (Special Diet Services,
Wiltham, UK). Monoclonal antibody was concentrated from
the tissue culture supernatant of a hybridoma using a protein
A-Sepharose column as described (Todorov et al, 1996b). The
human melanoma cell line, G361, was obtained from the European
Collection of Cell Cultures (Porton Down, Wilts, UK). Affi-Gel
Hz was purchased from Bio-Rad (Hemel Hempstead, UK).
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Summary Human melanoma, G361, which induces cachexia in nude mice, has been shown to produce a proteolysis-inducing factor (PIF) of
Mr 24 000, which is immunologically identical to that isolated from a cachexia-inducing murine tumour (MAC16). Biosynthetic labelling of
G361 cells using a combination of [35S]sulphate and [6-3H]glucosamine gave a single component of Mr 24 000 after affinity chromatography
employing a murine monoclonal antibody. The material contained both radiolabels and, after digestion with peptide N-glycosidase F, two
fragments were produced of Mr 14 000 and 10 000 also containing both radiolabels. Digestion with O-glycosidase produced three fragments
of Mr 14 000, 6000 and 4000, the first two of which contained both radiolabels, while the third only contained 3H. This digestion pattern is the
same as that previously observed with PIF from the MAC16 tumour and is commensurate with one N-linked sulphated oligosaccharide chain
of Mr 10 000, one O-linked sulphated oligosaccharide chain of Mr 6000 and a central polypeptide chain of Mr 4000 with some residual
carbohydrate. When PIF from G361 cells was administered to female NMRI mice (20 g) a pronounced depression of body weight
(1.36 ± 0.36 g; P < 0.0001 from control) was observed over a 24 h period without a decrease in either food or water consumption. Body
composition analysis showed a significant decrease in the non-fat carcass mass without a change in carcass fat or body water. This result
suggests that depletion of lean body mass in mice bearing G361 melanoma arises from the production of PIF.
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Cell culture and radiolabelling procedures
G361 cells were maintained in McCoys 5a medium supplemented
with 2 mM glutamine and 10% FBS under an atmosphere of 5%
carbon dioxide (CO2) in air. Cells were plated in McCoys 5a
medium containing Na2
35SO4 (1 mCi ml–1) and [3H]glucosamine
(2 mCi ml–1) and allowed to grow for 48 h at 37°C under an atmos-
phere of 5% CO2 in air. Cells were removed from the substratum
with trypsin–EDTA and sedimented by low speed centrifugation
(1500 rpm for 5 min on a bench-top centrifuge) followed by
washing in phosphate-buffered saline (PBS). The cell pellet was
resuspended in 1 ml of 10 mM Tris–HCl (hydrochloric acid),
pH 8.0, containing 0.5 mM phenylmethylsulphonyl fluoride
(PMSF), 0.5 mM EGTA and 1 mM dithiothreitol, and dissociated
using an ultrasonic oscillator. Debris was removed by centrifuga-
tion (15 000 rpm for 20 min); solid ammonium sulphate (80%
w/v) was added to the supernatant and the mixture was stored
overnight at 4°C. The precipitated proteins were collected by
Figure 1 Immunoblot of PIF affinity purified from G361 (lane 1) and MAC16
(lane 2) cells detected using monoclonal antibody, which had been
biotinylated using the ECL protein biotinylation module (Amersham UK).
Samples were electrophoresed on 15% sodium dodecyl sulphate
polyacrylamide gels, transferred to nitrocellulose membranes blocked with
5% Marvel in 0.15% Tween-20 in PBS. Filters were washed and incubated
for 1 h with 10 mg ml–1 biotinylated antibody. After further washing, filters were
incubated for a further 1 h with streptavidin–horseradish peroxidase
conjugate (Amersham) and bands were detected with an emission
chemiluminescence (ECL) system
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Figure 2 Elution profile of biosynthetically labelled, affinity purified PIF isolated from G361 cells and chromatographed on a Sephadex G-50 column
(40 ´ 1.5 cm). The column was equilibrated with 10 mM Tris–HCl, pH 7.0 containing 0.2 M sodium chloride and eluted at 6 ml h–1. Fractions (0.7 ml) were
collected and assayed for 35S (•) and 3H (l l) radioactivity using a dual counting procedure. (A) Without treatment. (B) After incubation for 24 h with
protease-free recombinant PNGase F (1 unit per 20 ml) at pH 8.0 and 37°C. The enzyme was also free of endo-a-N-acetylgalactosaminidase
H/endo-a-N-acetylgalactosaminidase F and glycosidase. (C), after incubation for 20 h with O-glycosidase (1 m unit per 20 ml) in 100 mM phosphate–citrate,
pH 6.0. The enzyme was free of protease and contaminating glycosidases. Treatment with the incubation buffers alone had no effect on the elution position
of the Mr 24 000 material1736 PT Todorov et al
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centrifugation and the pellet resuspended in the sonicating buffer.
Salt was removed by ultrafiltration with an Amicon filtration cell
containing a membrane filter with a molecular weight cut-off of
10 000 against the same solution. The concentrated sample was
loaded onto an affinity column containing mouse monoclonal anti-
body coupled to Affi-Gel Hz (Todorov et al, 1996b) equilibrated
with 10 mM Tris–HCl, pH 8.0 at 4°C. After overnight circulation
at a flow rate of 5 ml h–1 the column was washed with 10 mM
Tris–HCl, pH 8.0, and the retained material was eluted with
100 mM glycine HCl, pH 2.5. The fractions were counted for
radioactivity using a Packard 2000 CA liquid scintillation analyser
and the fractions containing radioactivity were neutralized with
1 M Tris–HCl, pH 8.0, concentrated by Amicon filtration and
subjected to exclusion chromatography on a Sephadex G-50
column. Non-radioactive PIF was also purified from MAC16 and
G361 cells using affinity chromatography.
Animal studies
Female NMRI mice (five per group; average weight 20.6 g) were
injected intravenously (i.v.) into the tail vein with PIF (7 mg
protein in 100 ml PBS) at 1.5 h intervals over a 6 h period (total of
four injections). Control animals received PBS alone. Body weight
and food and water intake were monitored and the animals were
sacrificed 24 h after the first injection. Each carcass was weighed,
placed in an oven at 80°C until constant weight was reached and
re-weighed. The total fat content of the carcass was determined by
the method of Lundholm et al (1980). The residue was the non-
fat mass. The water content was calculated from the difference
between the wet and dry weights.
RESULTS
PIF was isolated from G361 cells by an initial 40% ammonium
sulphate ((NH4)2SO4) precipitation followed by affinity chro-
matography using monoclonal antibody specific to PIF (Todorov
et al, 1996b). Western blotting of immunoaffinity purified material
gave evidence for a single antigen of Mr 24 000 identical to that
isolated from the MAC 16 tumour (Figure 1).
In order to evaluate the number, size and attachment of the
oligosaccharide chains to the central polypeptide core in human
PIF, G361 cells were metabolically labelled with 35SO4 and [6-3H]-
glucosamine, which specifically labels the carbohydrate fraction.
Immunoaffinity purification gave a single band of radioactivity
containing both radioisotopes. The apparent molecular weight as
determined by exclusion chromatography on Sephadex G-50
was 24 000 in comparison with standard proteins (Figure 2A).
Re-chromatography of this material after overnight digestion with
PNGase F produced two bands of radioactivity eluting at positions
corresponding to Mr 14 000 and 10 000 (Figure 2B). Both
fragments contained 3H and 35S. Digestion of the Mr 24 000
material with O-glycosidase followed by re-fractionation on
Sephadex G50 showed conversion to three bands of radioactivity
corresponding to Mr 14 000, 6000 and 4000 (Figure 2C). The first
two fragments contained both radiolabels, while the third only
contained  3H.
To evaluate the biological effectiveness of PIF produced by
G361, affinity-purified material was administered i.v. to female
NMRI mice and changes in body weight and body composition
were determined after 24 h (Table 1). Animals receiving PIF
showed a 6.6% decrease in body weight over 24 h, while PBS-
treated controls showed a 5% increase in body weight. The differ-
ence was highly significant (Table 1). There was no difference in
food and water consumption between the groups. Body composi-
tion analysis showed a significant reduction in the non-fat carcass
mass (Table 1), with no change in water or fat content. This
suggests that PIF produced by the G361 cell line is biologically
active.
DISCUSSION
Using a monoclonal antibody derived from splenocytes of mice
bearing the cachexia-inducing MAC16 tumour we have been able
to identify an antigen of Mr 24 000, which is immunologically
identical both in the MAC16 tumour and in the urine of patients
with cachexia and a variety of tumour types (Todorov et al,
1996a). This antigen is a sulphated glycoprotein (Todorov et al,
1997) with a central polypeptide core, the amino acid sequence of
which is also identical in both mouse (Todorov et al, 1996a) and
man (Cariuk et al, 1997). Material from both sources caused a
rapid loss of body weight in non-tumour-bearing mice by specific
depletion of the non-fat carcass mass (Todorov et al, 1996a;
Cariuk et al, 1997).
In the present study material of identical molecular weight to
that isolated from the MAC16 tumour has been purified from
human melanoma cells, G361, confirming the tumour origin of the
human product. This material has also identical immunoreactivity
with the mouse monoclonal antibody, which recognizes the carbo-
hydrate chains in the glycoprotein (Todorov et al, 1997). In addi-
tion, the number, size and attachment of the oligosaccharide chains
to the peptide core is the same in the G361 product as that isolated
from the MAC16 tumour. Incubation of PIF from G361 cells with
recombinant protease-free PNGase F, which specifically cleaves
the N-acetylglucosamine–asparagine bond of N-linked oligos-
accharides (Tarentino et al, 1985), yielded two fragments of
Mr 14 000 and 10 000, both of which were sulphated, as previously
observed with PIF isolated from the MAC16 tumour (Todorov
et al, 1997). The fragment of Mr 10 000 has been attributed to a
N-linked oligosaccharide chain, while the fragment of Mr 14 000
represents the peptide core and residual oligosaccharide.
Treatment of PIF from G361 cells with O-glycosidase, which has
stringent specificity for the core structure Gal b1®3 Gal NAc
a1-Ser/Thr, yielded a fragment of Mr 6000, representing an
O-linked sulphoglycan chain (Todorov et al, 1997) and a fragment
of Mr 4000 labelled with 3H alone, representing the core peptide
with some carbohydrate attached. Thus the size and attachment of
the oligosaccharide chains in the human PIF is the same as pre-
viously reported in the mouse (Todorov et al, 1997).
Table 1 Effect of PIF isolated from G361 cells on body weight and body
composition of female NMRI micea
Parameter Control PIF P b
Weight change over 24 h (g) + 1.02 ± 0.39 –1.36 ± 0.36 0.0001
Food intake (g) 3.6 3.3 NS
Water intake (ml) 3.8 3.8 NS
Body water (%) 67.2 ± 0.3 66.4 ± 1.5 NS
Non-fat (g) 7.26 ± 0.08 6.19 ± 0.32 0.01
Fat (g) 1.39 ± 0.07 1.44 ± 0.13 NS
aValues are given as mean ± s.e.m. for five mice per group. bDifferences
between control and PIF groups were determined by Student’s t-test.Role of a proteolysis-inducing factor in cachexia 1737
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Production of cachexia by G361 cells in nude mice has pre-
viously been attributed to the expression of LIF (Mori et al, 1991).
LIF has been suggested to play a role in the cancer cachexia
syndrome through the ability to decrease lipoprotein lipase (LPL)
activity (Marshall et al, 1994). Inhibition of LPL would prevent
adipocytes extracting fatty acids from plasma lipoproteins for
storage, resulting in a net flux of lipid into the circulation. No
mechanism has been proposed for catabolism of skeletal muscle
by LIF. Inhibition of LPL alone would not produce cachexia, since
none is seen in type 1 hyperlipidaemia caused by an inherited
deficiency of LPL. Although exogenously administered, recombi-
nant LIF has been shown to induce loss of body weight in experi-
mental animals, this has been reported as only occurring at dose
levels near the toxic limit (Metcalf et al, 1990). The loss of body
weight was ascribable to a complete loss of subcutaneous and
intra-abdominal fat with no change in liver and kidney weights,
suggesting that the weight loss was not a true cachexia. This
suggests that factors other than LIF may be responsible for the
cachexia induced by G361 cells.
In this study we have shown that PIF, purified from G361 cells,
is capable of producing loss of body weight in mice, with specific
loss of the carcass non-fat mass. There was no loss of adipose
tissue and no decrease in food intake as would be expected with
LIF. Thus it is likely that G361 melanoma cells produce cachexia
as a result of expression of PIF rather than LIF.
This study has shown that human melanoma cells produce a PIF
which is structurally and functionally identical with the mouse
factor. Further studies are required to establish the degree of
homology of the gene coding for the central polypeptide chain in
the two species.
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